Roche’s Genentech To Present Pivotal Lung And Breast Cancer Data At ESMO 2026, Highlighting Divarasib Superiority Over Standard Of Care And Giredestrant Efficacy Gains Without Tolerability Or Quality-Of-Life Compromise
Phase III Krascendo 1 results demonstrated divarasib’s superiority over current standard of care, first-generation KRAS G12C inhibitors, in previously treated advanced G12C-mutated non-small cell lung
Roche's cancer drugs showed better results than older treatments in testing. When a company proves its medicine works well, people watch to see if doctors will use it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.